日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
World
Home / World / China-US

New medicine for prostate cancer available in China

chinadaily.com.cn | Updated: 2019-11-28 16:49
Share
Share - WeChat

New medicine to treat patients with non-metastatic castration-resistant prostate cancer (nmCRPC) is available in China to save those at high risk of developing metastases.

The Xian Janssen Pharmaceutical Ltd announced on Wednesday that ERLEADA (apalutamide) was put on the market in China after being granted by the China National Medical Products Administration (NMPA) in September, recognizing the urgent unmet need for patients with nmCRPC who currently have few treatment options.

ERLEADA is an androgen receptor inhibitor that works by preventing androgen from binding to the androgen receptor. It has been shown to delay the time to distant metastasis. Treatment with ERLEADA has also shown to result in the control of Prostate-Specific Antigen (PSA) levels, which is an important indicator during the early treatment and prognosis of patients with prostate cancer.

According to Professor Zhou Liqun, Head of Urology Department in Peking University First Hospital, the five year survival rate for advanced mCRPC patients is only 3% before the new method of endocrine treatment. "This rate increased to only 30% even with new treatment. So it is urgent to postpone progression and to maintain quality of life for patients living with nmCRPC and the approval of ERLEADA presents a new treatment option that can potentially addres this treatment.

The incidence rate of prostate cancer in China has increased and become one of the top five of the most common male cancers in the country over the past decade. The androgen-deprivation therapy (ADT) is the current standard of care for nmCRPC. However, if after initial sustained treatment with ADT, the cancer cells continue to progress without distant metastasis, patients will enter a stage called nmCRPC. Without interventions, 90% of patients with nmCRPC will eventually develop bone metastases, which can lead to pain, fractures and spinal cord compression.

According to data from a clinical study, ERLEADA reduced the risk of advanced metastasis or death by 72% and increased median metastasis-free survival by over two years among patients with nmCRPC who are undergoing continuous ADT treatment.

Professor Wang Jianye, Dean of Beijing Hospital and Director of National Center of Gerontology, said "In recent years, urology and oncology doctors are working on new NM-CRPC treatment and medicine. ERLEADA optimizes the standard NM-CRPC treatment in China and provides quality time for patients and their families."

"As one of the leading pharmaceutical companies in China, Xian Janssen has been dedicated to helping patients with prostate cancer in China. We recognize the varied needs of patients across all stages of prostate cancer, which require collaborative efforts from government, society and the healthcare industry to address. To help patients with prostate cancer receive better treatment, we are committed to exploring the full potential of our solutions in addressing unmet treatment needs across all stages of disease progression," said Asgar Rangoonwala, President of Xian Janssen.

ERLEADA is now available in major Chinese cities including Beijing, Shanghai, Guangzhou and Tianjin. Xian Janssen is supporting the China Primary Healthcare Foundation to launch a Patient Access Program that helps low-income patients in China access treatment with ERLEADA.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 欧美精品二区三区 | 国产精品冒白浆免费视频 | 特级丰满少妇一级aaaa爱毛片 | 亚洲视频在线视频 | 久久婷婷是五月综合色狠狠 | 亚洲成a人v大片在线观看 | 欧美a级成人淫片免费看 | 狠狠色丁香婷婷综合橹不卡 | 台湾av在线 | 亚洲精品久久久久久一区二区 | 无遮挡羞羞视频 | 五月婷六月丁香狠狠躁狠狠爱 | 4hu在线| 欧美日韩精品一区二区在线播放 | 免费高清成人啪啪网站 | 99热免费精品 | 一级黄色绿像片 | 波多野结衣hd在线播放 | 亚洲视频在线播放 | 天天天天综合 | 色视在线 | 麻豆专区一区二区三区四区五区 | 免费一区二区三区 | 中文字幕 国产精品 | 男女免费在线视频 | 国产91亚洲精品 | 99国产精品久久久久久久成人热 | 91精品久久久久久久久网影视 | 国产精品视频分类 | 波多在线 | 日本免费在线一区 | 日韩中文字幕网 | 99成人精品视频 | 日韩中文字幕在线观看视频 | 亚洲精品一区二区三区四区 | 亚洲播播播| 成人av网站免费观看 | 欧美日韩在线免费观看 | 国内精品一区二区 | 亚洲美女一区二区三区 | 精品在线一区 |